E! 942, OxidoResist, HDxperts AB
| Reference number | |
| Coordinator | Biomotif AB |
| Funding from Vinnova | SEK 4 950 925 |
| Project duration | July 2022 - December 2025 |
| Status | Ongoing |
| Venture | Eurostars |
Purpose and goal
** Denna text är maskinöversatt ** The OxidoResist project aims to develop a technology to overcome drug resistance against cancer. OxidoResist technology will apply the innovative single-cell proteomics and modern AI-based bioinformatics to discover which FDA-approved drugs will overcome resistance in combination with the anticancer drug under study. We will develop a universal pipeline for the discovery of optimal drug combinations that overcome resistance to target-specific therapies.
Expected effects and result
** Denna text är maskinöversatt ** The project aims to develop and introduce two new products on the market - 1) Medicines against cancer with a new mechanism of action, 2) Service platform
Planned approach and implementation
The OxidoResist project aims to develop a technology to overcome anticancer drug resistance. The OxidoResist technology will apply the innovative single cell proteomics and modern AI-based bioinformatics to discover which FDAapproved drug(s) will overcome resistance in combination with the anti-cancer drug under study. We will develop a universal pipeline (joining top wet labs, AIbased bioinformatics, chemoinformatics, and network modeling) for the discovery of optimal drug combinations overcoming resistance to targetspecific therapeutics.